Creatine energizes the entire system that guides the cancer fighters
In the long human struggle against cancer, a UCLA research team has found an unexpected ally in creatine — a molecule long associated with athletic endurance — that may strengthen the immune system's own training infrastructure. The discovery centers on dendritic cells, the scouts that prepare the body's killer T cells for battle, which currently go undernourished in the tumor environment, leaving the majority of immunotherapy patients without benefit. By energizing these cellular instructors rather than the fighters themselves, creatine may offer a way to bring more patients into the reach of treatments that already exist.
- Only 20 to 40 percent of cancer patients respond to current immunotherapies — a gap that has long frustrated oncologists and left millions without effective options.
- UCLA researchers traced the problem upstream: dendritic cells inside tumors are metabolically starved, unable to properly train the killer T cells meant to destroy cancer.
- When creatine was removed from dendritic cells in the lab, immune activation collapsed; when it was added back, tumor growth slowed and immune cell infiltration surged in mouse models.
- Human cell tests confirmed the effect — creatine-boosted dendritic cells showed enhanced activation and stronger stimulation of T cells against cancer targets.
- The path forward requires clinical trials, but two near-term applications are already in view: creatine as a patient supplement during immunotherapy, and as a potency enhancer in dendritic cell vaccine manufacturing.
A UCLA research team has discovered that creatine, the supplement long favored by athletes, may carry unexpected power in cancer treatment — not by targeting tumors directly, but by strengthening the immune system's support structure. The study, published in iScience, focuses on dendritic cells: specialized scouts that detect cancer and train the body's killer T cells to respond. Current immunotherapies work by supercharging those T cells directly, yet they help only 20 to 40 percent of patients. Senior author Lili Yang and her team believe creatine could widen that window by energizing the system that guides the fighters, not just the fighters themselves.
The researchers began by examining which metabolic genes were most active in dendritic cells that had infiltrated mouse tumors. They found that the gene encoding the creatine transporter was significantly elevated in tumor-dwelling dendritic cells compared to those in healthy tissue. When they engineered cells that lacked this transporter entirely, the results were stark: the cells struggled to survive, activated poorly, and failed to prime T cells effectively. In laboratory dishes, T cells paired with creatine-deficient dendritic cells divided less and produced fewer of the chemical signals needed to fight cancer.
Reversing the experiment proved equally telling. Mice with melanoma that received daily creatine injections showed significantly slowed tumor growth, along with higher numbers of activated dendritic cells inside their tumors. Metabolomics analysis revealed that creatine raised ATP levels — the cell's energy currency — inside dendritic cells, allowing them to sustain the inflammatory signaling needed for activation even while competing with fast-growing tumor cells for nutrients. The effect extended to human cells: creatine enhanced the activation of human dendritic cells and improved their ability to stimulate T cells against cancer-associated targets.
Graduate student and co-first author James Elsten-Brown outlined two practical paths forward — creatine as a supplement for patients already receiving immunotherapy, or as an additive during dendritic cell vaccine manufacturing to boost potency before administration. The team was careful to note that all experiments were conducted in cells and mice, not human patients, and that anyone in cancer treatment should consult their physician before adding any supplement. UCLA has filed a patent application on the findings, and the researchers are now seeking clinical partners to test whether the laboratory results translate to real patient outcomes.
A UCLA research team has found that creatine, the supplement long favored by athletes seeking muscle gains, may hold unexpected power in the fight against cancer. The discovery centers not on the tumor-fighting cells themselves, but on the immune system's support structure—specialized cells called dendritic cells that scout for cancer and activate the body's killer T cells to attack.
Current cancer immunotherapies work by supercharging killer T cells directly, yet they only help between 20 and 40 percent of patients who receive them. The new research, published in iScience, suggests that creatine could widen that window by strengthening the dendritic cells that train and prepare those T cells for battle. Lili Yang, the study's senior author and a professor of microbiology, immunology and molecular genetics at UCLA, framed the finding this way: creatine doesn't just energize the fighters—it energizes the entire system that guides them. That distinction matters. It means creatine could potentially bring immunotherapy's benefits to patients who currently don't respond to it.
The researchers began by studying which metabolic genes were most active in dendritic cells that had infiltrated tumors in mice. They discovered that the gene responsible for producing the creatine transporter—the protein that allows cells to absorb creatine—was significantly elevated in tumor-dwelling dendritic cells compared to those in healthy tissue. To understand why this mattered, the team engineered dendritic cells that lacked the creatine transporter entirely. These cells struggled to survive, showed reduced activation, and performed poorly at priming T cells to mount an anti-tumor response. When these creatine-deficient dendritic cells were placed alongside T cells in a laboratory dish, the T cells divided less frequently and produced fewer of the chemical signals needed to fight cancer.
The team then reversed course. Instead of removing creatine, they increased it. Mice with melanoma that received daily creatine injections showed significantly slowed tumor growth. The treatment boosted both the number and activation level of dendritic cells that had infiltrated the tumors. These creatine-treated dendritic cells also released higher levels of chemical signals that recruit additional immune cells into the tumor microenvironment. Using metabolomics analysis, the researchers found that creatine supplementation raised ATP levels—the energy currency that powers cellular functions—inside dendritic cells and sustained the inflammatory signaling pathways necessary for activation. Creatine essentially acts as a battery, allowing dendritic cells to maintain stable energy levels even when competing with fast-growing tumor cells for nutrients.
The findings extended to human cells. When the team tested creatine on human dendritic cells derived from monocytes—the type often used in dendritic cell cancer vaccines—the supplement enhanced their activation and improved their ability to stimulate human T cells against cancer-associated targets. James Elsten-Brown, a co-first author and graduate student in Yang's lab, outlined two potential applications: creatine could be given as a supplement to patients already receiving immunotherapy, or incorporated into dendritic cell vaccines during manufacturing to boost their potency before administration.
The researchers were careful to emphasize the limits of their work. The experiments were conducted in cells and mice, not in human patients. Although creatine monohydrate has been used safely as a supplement for decades at recommended doses, anyone undergoing cancer treatment should consult their physician before adding any supplement. The team is now seeking to partner with clinicians on prospective clinical trials that could test whether creatine supplementation actually improves outcomes in patients receiving immunotherapy. The findings are covered by a patent application filed by UCLA's Technology Development Group, and the next phase of this research will determine whether what works in the laboratory translates to the clinic.
Notable Quotes
Creatine doesn't just help the T cells fighting cancer—it also energizes the entire infrastructure that supports and guides them— Lili Yang, UCLA study senior author
Creatine could be used as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve dendritic cell-based vaccines— James Elsten-Brown, co-first author and graduate student
The Hearth Conversation Another angle on the story
Why does it matter that creatine helps dendritic cells specifically, rather than just the T cells directly?
Because dendritic cells are the immune system's scouts and teachers. They find the tumor, capture its fragments, and then recruit and activate the T cells that actually kill cancer. If you only boost the T cells without strengthening the cells that guide them, you're giving soldiers weapons but no map. Creatine appears to work on both.
The study mentions that only 20 to 40 percent of patients respond to current immunotherapies. Does creatine solve that problem?
Not necessarily solve it, but potentially expand it. The researchers are saying that some patients may not respond because their dendritic cells are energy-starved in the tumor environment. Creatine could help those cells maintain the energy they need to do their job. But that's still a hypothesis. They need human trials to know if it actually changes outcomes.
If creatine is already sold as a supplement, why hasn't this been discovered before?
Creatine's been studied mainly for muscle performance and strength. The metabolic role it plays in immune cells—especially in the specific context of tumor immunity—is newer territory. The researchers had to specifically look at which genes were active in dendritic cells inside tumors to even notice the creatine transporter was elevated. That's targeted investigation, not casual observation.
What's the difference between giving creatine as a patient supplement versus building it into a vaccine?
One is about supporting the immune response while it's already happening. The other is about manufacturing a better vaccine from the start. If you're making dendritic cell vaccines in the lab, you could grow those cells in creatine-enriched conditions so they arrive at the patient already primed and energized. Two different entry points, same molecule.
How confident should patients be about this right now?
Not confident enough to start taking creatine supplements on their own. This is mouse and cell work. The researchers themselves say no medical recommendations should be drawn from it yet. What you should watch for is whether the clinical trials actually happen and what they show. That's when the real answer emerges.